Author Archives: Stefan Avall
Kardium Announces $104M in New Financing for Innovative Atrial Fibrillation Treatment
06/11/2024
Private financing round supported by Fidelity Management & Research Company, T. Rowe Price and Durable Capital Partners June 11, 2024 09:00 AM Eastern Daylight Time VANCOUVER, British Columbia —Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $104 million in a new financing round. The round is led […]
05/29/2024
Vancouver, BC — Kardium Inc., a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF), announced positive results of the 1-year outcomes of the First-in-Human PULSE-EU Trial. These findings were presented as late-breaking clinical data at the Heart Rhythm Society (HRS) 2024 Annual Meeting and simultaneously published in the Heart […]
05/09/2024
Vancouver, BC — Kardium Inc., a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF), announced today that it had successfully treated a series of patients delivering therapy in both the left and right atria. After successfully completing pulmonary vein isolation (PVI) and posterior wall ablation in […]
Kardium Announces Completion of Paroxysmal Enrollment in the PULSAR IDE Study
04/02/2024
(Vancouver | April 2, 2024) — Kardium Inc., a private medical device company that has developed the Globe® System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today the successful completion of enrollment in the paroxysmal cohort of the pivotal PULSAR IDE (Investigational Device Exemption) study. This achievement marks a […]
Kardium Announces First US Procedures in PULSAR Study of Globe® Pulsed Field System
05/31/2023
(Vancouver | May 31, 2023) Kardium Inc., a private medical device company that has developed the Globe System for the treatment of atrial fibrillation (AF) using pulsed field ablation (PFA), announced today that the first US patients have been successfully treated in the PULSAR clinical study. The PULSAR study will enroll over 400 patients for […]